Celcuity Inc. (CELC) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Celcuity Inc. is a clinical-stage biotechnology company focused on developing gedatolisib, a kinase inhibitor targeting the PI3K/AKT/mTOR pathway for solid tumors. The company has no product revenue to date and is currently preparing for the commercial launch of gedatolisib pending FDA approval.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(52.8) million | $(37.0) million |
| Net Loss Per Share | $(0.97) | $(0.86) |
| Cash & Cash Equivalents | $145.2 million | $16.5 million |
| Short-term Investments | $241.9 million | $275.8 million |
| Total Liquidity (Cash + Investments) | $387.1 million | $292.3 million |
| Convertible Notes (Carrying Value) | $195.6 million | $195.3 million |
| Note Payable (Carrying Value) | $127.9 million | $126.5 million |
| Accumulated Deficit | $(501.7) million | $(308.9) million |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased 40% to $50.5 million.
- Research & Development (R&D): Increased 11% to $33.1 million, driven by higher employee/consulting costs and manufacturing, partially offset by lower clinical trial costs for VIKTORIA-1.
- Selling, General & Administrative (SG&A): Increased 174% to $17.4 million, primarily due to commercial headcount additions and launch-related activities in anticipation of FDA approval.
- Interest Expense: Increased 91% to $6.1 million due to the issuance of $201.3 million in Convertible Notes in July 2025 and the drawdown of the $30.0 million Term D Loan in September 2025.
- Liquidity Position: Cash and cash equivalents decreased by $20.5 million during the quarter due to operating cash outflows of $55.1 million, partially offset by net investment proceeds of $34.5 million.
Outlook, Guidance, and Risks
- Regulatory Status: The FDA accepted the New Drug Application (NDA) for gedatolisib in HR+/HER2- PIK3CA WT advanced breast cancer in January 2026. The application is under Priority Review with a PDUFA goal date of July 17, 2026.
- Clinical Milestones:
- VIKTORIA-1 (WT Cohort): Demonstrated statistically significant improvement in Progression-Free Survival (PFS) with hazard ratios of 0.24 (triplet) and 0.33 (doublet) vs. fulvestrant.
- VIKTORIA-1 (MT Cohort): Positive topline results announced May 1, 2026, showing significant PFS improvement vs. alpelisib.
- VIKTORIA-2: Ongoing Phase 3 trial for first-line treatment; protocol amended in May 2026 to include endocrine-sensitive patients and change control arms.
- Liquidity Outlook: Management believes current cash, investments, and available borrowings will fund operations through 2027.
- Risks: Key risks include the uncertainty of FDA approval, the ability to commercialize gedatolisib, potential need for additional capital, and the complexity of clinical trial execution. The company carries significant debt obligations with financial covenants.
Investor Verification Checklist
- Verify the July 17, 2026 PDUFA date and monitor for any FDA Complete Response Letters or approval decisions.
- Confirm the status of the VIKTORIA-2 protocol amendments and enrollment progress following the May 2026 changes.
- Review the debt covenants in the Amended A&R Loan Agreement and Convertible Notes to ensure compliance with liquidity requirements.
- Monitor cash burn rate given the 174% increase in SG&A expenses as the company scales commercial infrastructure.
- Assess the timeline for the subcutaneous formulation patent application announced in May 2026 and its potential impact on market access.